Aetna considers breast reconstructive surgery to correct breast asymmetry to be cosmetic in all situations except the explicitly listed exceptions. Exceptions include: (1) surgical correction of chest wall deformity causing a functional deficit in Poland syndrome when criteria in CPB 0272 are met; and (2) repair of breast asymmetry that is the direct result of a medically necessary mastectomy or lumpectomy that produces a significant deformity. In those exception cases, procedures on the unaffected breast to achieve symmetry (for example, areolar/nipple reconstruction or tattooing, augmentation with an FDA‑approved internal breast prosthesis, implant removal/re‑implantation, reduction mammoplasty, mastopexy, capsulectomy, capsulotomy, and reconstructive revisions) are considered medically necessary when performed to produce a symmetrical appearance.

Autologous fat grafting (lipomodelling) is described as a technique to improve contour or restore volume but has variable effectiveness and important safety concerns. Case series report wide variability in outcomes (substantial improvement reported in 21%–86.5% of patients) and an approximate 7% rate of lipo‑necrotic lumps. These nodules, calcifications, cysts, and indurations can produce abnormalities on cancer screening and may impede future cancer detection; long‑term follow‑up and imaging (mammography, ultrasound, CT, MRI) are recommended after the procedure.

The “body lift” perforator flap technique — a layered or circumferential trunk donor approach to provide additional volume for autologous reconstruction in thin patients — has been reported in small case series but is currently judged to have insufficient evidence to support routine use for breast reconstruction. Major clinical reviews and UpToDate summaries do not describe this technique as a standard management option, and further well‑designed studies are needed to validate safety and outcomes.

Immediate expander‑implant breast reconstruction (EIBR) in patients with prior pre‑mastectomy external beam radiation therapy (XRT) is associated with substantially higher complication and failure rates compared with non‑irradiated patients. In one retrospective series, the EIBR failure rate was reported at 50.0% for the pre‑operative XRT group versus 13.3% in controls (p = 0.044). The authors recommend that patients with a history of pre‑mastectomy radiation strongly consider autologous reconstruction to avoid the higher risk of complications and implant loss with EIBR.

Evidence summaries and recent reviews note that 3D volumetric imaging and 3D‑printed templates have been evaluated in small observational series and may assist preoperative planning (for example, improved implant sizing prediction and reduced intraoperative perforator identification time). However, an UpToDate overview of breast reconstruction (Nahabedian, 2021) does not list 3D volumetric imaging among standard management tools, reflecting limited adoption in mainstream clinical references and the need for further validation before routine use.

The policy lists nerve coaptation / neurotization among procedures for which the current evidence is insufficient to establish clear effectiveness (classified as experimental and investigational in this CPB). Within the provided excerpt there is no explicit coverage exclusion or definitive payer stance on neurotization beyond its inclusion in the experimental/investigational list; the background summarizes promising but heterogeneous study results and calls for additional standardized research.

The excerpt contains no specific site‑exit coverage exclusions for additional procedures beyond those enumerated in the policy. The final chunk is a site‑exit disclaimer and does not state any further coverage restrictions or exclusions beyond the policy text already cited.

The policy references specific procedure and technology codes in its coverage discussion. Notably, CPT code 0694T (3‑dimensional volumetric imaging/reconstruction) is identified in the document as an item of concern (listed under experimental/not covered in the CPB), and nerve graft/allograft procedure codes 64910–64913 are discussed in the context of nerve repair/coaptation techniques. These code references are provided to guide billing and to indicate that these technologies/procedures are addressed in the policy.

Although neurotization (nerve coaptation) is discussed in the background and listed among experimental/investigational procedures in the policy, the excerpt does not contain any explicit statement designating neurotization procedures as not medically necessary. The document instead summarizes the existing evidence and notes heterogeneity and the need for standardized outcome measurement before establishing a definitive coverage determination.

Breast reconstruction rebuilds breast shape after mastectomy using implants or autologous tissue and may require multiple staged procedures including nipple/areolar reconstruction and tattooing. Staged approaches include use of tissue expanders followed by implant placement or autologous flap reconstruction (eg, TRAM, DIEP, SIEA, GAP flaps). The policy notes that when reconstruction is medically necessary after mastectomy or lumpectomy, associated staged procedures and related services (including nipple/areolar reconstruction and tattooing) are part of the reconstructive plan and may be considered medically necessary when selection criteria are met.